Could a PARP inhibitor slow prostate cancer recurrence?
NCT ID NCT03047135
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the drug olaparib in 51 men whose prostate cancer has returned after surgery and is at high risk of spreading. Olaparib works by blocking a repair process that cancer cells rely on, especially those with certain DNA faults. The main goal is to see if the drug can lower PSA levels by at least half, which would suggest it is controlling the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Allegheny Cancer Center
Pittsburgh, Pennsylvania, 15212, United States
-
Johns Hopkins Hospital
Baltimore, Maryland, 21231, United States
-
Thomas Jefferson University
Philadelphia, Pennsylvania, 19107, United States
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Triple-Drug cocktail before surgery curb prostate Cancer's return?
- AI could slash MRI scan times without sacrificing quality
- New prostate surgery technique aims to shorten operation time
- New surgical clip tool tested in 161 patients
- Can a neighborhood talk save lives? prostate cancer education trial shows promise
- New drug SYS6043 targets Hard-to-Treat cancers in early trial